Dextenza is a sustained-release dexamethasone hydrogel intracanalicular insert for the treatment of ocular pain and inflammation after ophthalmic surgery. The insert is a rod-shaped biodegradable hydrogel intracanalicular device that delivers 0.4 mg dexamethasone in sustained and tapered release over 4 weeks. The hydrogel is conjugated with fluorescein to enable visualization through eye tissue for retention monitoring. Dextenza is inserted through the inferior punctum into the canaliculus of the operative eye following surgery. It does not require removal after therapy. The device dissolves after remaining in the eye for approximately 30 days and is cleared through the nasolacrimal duct.
If you have a Hayes login, click here to view the full report on the Knowledge Center.